{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:12:21Z","timestamp":1793261541283,"version":"4.5.0"},"reference-count":122,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>PLAIN ENGLISH SUMMARY<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\u2009<\/jats:title>\n                    <jats:p>In this article the authors review recent advances in the treatment of chronic kidney disease (CKD) with diabetes, and summarize evidence supporting combination therapy approaches to improve patient outcomes. Driven by the global rise in diabetes, the worldwide burden of CKD has nearly doubled since the 1990s. People with CKD have notably increased risks for premature cardiovascular disease (heart and blood vessels disease), kidney failure and death. CKD, diabetes, obesity and cardiovascular disease are closely interrelated and share common risk factors. These health conditions therefore comprise what is now known as cardiovascular\u2013kidney\u2013metabolic (CKM) syndrome. Recently approved medications, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the non-steroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone, represent agents capable of reducing metabolic, kidney and cardiovascular risk through complementary mechanisms of action. Current evidence supports use of these therapies in combination. Besides providing additive protective effects, combination therapy may also help reduce side effects. For instance, using an SGLT2 inhibitor in combination with finerenone helps decrease the risk for high potassium levels. Through the multipronged approach, combination therapy allows tailoring treatment for the individual patient characteristics and needs. Several planned and ongoing clinical trials continue to study the benefits of combination therapy in people with CKM syndrome. With building evidence supporting the use of combination therapy, it is crucial to raise awareness of the importance of this treatment approach and develop processes to incorporate new therapies into every day practice to support optimal care and improved outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ABSTRACT<\/jats:title>\n                    <jats:p>The global burden of chronic kidney disease (CKD) increased by nearly 90% in the period spanning 1990 to 2016, mostly attributed to an increase in the prevalence of CKD in diabetes. People living with CKD have an elevated lifetime risk for cardiovascular disease (CVD) when compared with the general population, with risk increasing in parallel with albuminuria and kidney function decline. Metabolic disease, CKD and CVD share common risk factors including neurohumoral activation, systemic inflammation and oxidative stress, thus prompting the introduction of a broader construct of cardiovascular\u2013kidney\u2013metabolic (CKM) syndrome. An important rationale for the introduction of this concept are recent and ongoing therapeutic advancements fundamentally changing CKM management. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the non-steroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone have shifted the therapeutic paradigm for patients with CKD and have emerged in rapid succession as cornerstones of guideline-directed medical therapy (GDMT). Recently completed clinical trials of aldosterone synthase inhibitors and endothelin receptor antagonists have additionally reported additive antiproteinuric effects on the background of renin\u2013angiotensin system and SGLT2 inhibition, with acceptable safety profiles. The sum of current evidence from both preclinical and clinical studies support combination therapy in the setting of CKD to achieve additive and potentially synergistic kidney and heart protection by addressing metabolic, hemodynamic, and pro-inflammatory and pro-fibrotic mechanistic pathways. This narrative review will discuss available evidence supporting combination GDMT in CKD with diabetes and additionally discuss ongoing and future trials evaluating the efficacy and safety of combination therapies for CKD with or without diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfae212","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T08:24:32Z","timestamp":1738743872000},"page":"i3-i17","source":"Crossref","is-referenced-by-count":70,"title":["Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5437-5700","authenticated-orcid":false,"given":"Radica Z","family":"Alicic","sequence":"first","affiliation":[{"name":"Providence Medical Research Center, Providence Inland Northwest Health , Spokane, WA ,","place":["USA"]},{"name":"Department of Medicine, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J","family":"Neumiller","sequence":"additional","affiliation":[{"name":"Providence Medical Research Center, Providence Inland Northwest Health , Spokane, WA ,","place":["USA"]},{"name":"College of Pharmacy and Pharmaceutical Sciences, Washington State University , Spokane, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-0103","authenticated-orcid":false,"given":"Katherine R","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Providence Medical Research Center, Providence Inland Northwest Health , Spokane, WA ,","place":["USA"]},{"name":"Department of Medicine, University of Washington , Seattle, WA ,","place":["USA"]},{"name":"Kidney Research Institute and Institute of Translational Health Sciences, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"2025020513212235900_bib1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1573403X14666180711124825","article-title":"Chronic kidney disease and cardiovascular disease: is there any relationship?","volume":"15","author":"Vallianou","year":"2019","journal-title":"Curr Cardiol Rev"},{"key":"2025020513212235900_bib2","volume-title":"Chronic Kidney Disease in the United States","author":"(CDC) CfDCaP","year":"2021"},{"key":"2025020513212235900_bib3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000534071","article-title":"Disease burden and epidemiological trends of chronic kidney disease at the global, regional, national levels from 1990 to 2019","volume":"148","author":"Ying","year":"2024","journal-title":"Nephron"},{"key":"2025020513212235900_bib4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","journal-title":"Lancet North Am Ed"},{"key":"2025020513212235900_bib5","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025020513212235900_bib6","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Diseases GBD, Injuries C","year":"2020","journal-title":"Lancet North Am Ed"},{"key":"2025020513212235900_bib7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12882-023-03391-z","article-title":"Global incidence and death estimates of chronic kidney disease due to hypertension from 1990 to 2019, an ecological analysis of the global burden of diseases 2019 study","volume":"24","author":"Liu","year":"2023","journal-title":"BMC Nephrol"},{"key":"2025020513212235900_bib8","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","article-title":"Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy","volume":"390","author":"Levin","year":"2017","journal-title":"Lancet North Am Ed"},{"key":"2025020513212235900_bib9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2025020513212235900_bib10","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet North Am Ed"},{"key":"2025020513212235900_bib11","volume-title":"USRDS Annual Data Report: Epidemiology of kidney disease in the United States","author":"United States Renal Data System","year":"2022"},{"key":"2025020513212235900_bib12","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.2215\/CJN.02980322","article-title":"Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease","volume":"17","author":"Tuttle","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025020513212235900_bib13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.kint.2023.12.003","article-title":"Mind the gap in kidney care: translating what we know into what we do","volume":"105","author":"Luyckx","year":"2024","journal-title":"Kidney Int"},{"key":"2025020513212235900_bib14","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"2025020513212235900_bib15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"2025020513212235900_bib16","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2025020513212235900_bib17","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2025020513212235900_bib18","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/dci23-0030","article-title":"Diabetic nephropathy: update on pillars of therapy slowing progression","volume":"46","author":"Naaman","year":"2023","journal-title":"Diabetes Care"},{"key":"2025020513212235900_bib19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2337\/cd22-0110","article-title":"Perspectives on chronic kidney disease with type 2 diabetes and risk management: practical viewpoints and a paradigm shift using a pillar approach","volume":"41","author":"Morales","year":"2023","journal-title":"Clin Diabetes"},{"key":"2025020513212235900_bib20","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2025020513212235900_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2025020513212235900_bib22","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation","volume":"399","author":"Lingvay","year":"2022","journal-title":"Lancet North Am Ed"},{"key":"2025020513212235900_bib23","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1152\/physrev.00034.2018","article-title":"Mechanistic links between obesity, diabetes, and blood pressure: role of perivascular adipose tissue","volume":"99","author":"Saxton","year":"2019","journal-title":"Physiol Rev"},{"key":"2025020513212235900_bib24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.kisu.2021.11.004","article-title":"Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease","volume":"12","author":"Nakamura","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"2025020513212235900_bib25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000515622","article-title":"Aldosterone and Mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from Hans Selye to the present","volume":"52","author":"Epstein","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025020513212235900_bib26","doi-asserted-by":"publisher","first-page":"e05","DOI":"10.15420\/ecr.2021.52","article-title":"Arrhythmias in chronic kidney disease","volume":"17","author":"Akhtar","year":"2022","journal-title":"Eur Cardiol"},{"key":"2025020513212235900_bib27","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int"},{"key":"2025020513212235900_bib28","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1056\/NEJM199106063242304","article-title":"Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus","volume":"324","author":"Tuttle","year":"1991","journal-title":"N Engl J Med"},{"key":"2025020513212235900_bib29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/ki.1992.274","article-title":"Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes","volume":"42","author":"Tuttle","year":"1992","journal-title":"Kidney Int"},{"key":"2025020513212235900_bib30","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/ndt\/gfae027","article-title":"Glomerular hyperfiltration as a therapeutic target for CKD","volume":"39","author":"Kanbay","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025020513212235900_bib31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/nep.14130","article-title":"Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?","volume":"28","author":"Chung","year":"2023","journal-title":"Nephrology"},{"key":"2025020513212235900_bib32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2337\/dbi16-0056","article-title":"Back to the future: glomerular hyperfiltration and the diabetic kidney","volume":"66","author":"Tuttle","year":"2017","journal-title":"Diabetes"},{"key":"2025020513212235900_bib33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2337\/dbi18-0007","article-title":"Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease","volume":"68","author":"Alicic","year":"2019","journal-title":"Diabetes"},{"key":"2025020513212235900_bib34","doi-asserted-by":"publisher","first-page":"F103","DOI":"10.1152\/ajprenal.00155.2001","article-title":"Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes","volume":"282","author":"Tuttle","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025020513212235900_bib35","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3390\/ijms23073439","article-title":"The role of advanced glycation end products and its soluble receptor in kidney diseases","volume":"23","author":"Steenbeke","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025020513212235900_bib36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2337\/db08-1328","article-title":"Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy","volume":"58","author":"Berthier","year":"2009","journal-title":"Diabetes"},{"key":"2025020513212235900_bib37","doi-asserted-by":"publisher","first-page":"7236","DOI":"10.3390\/ijerph18147236","article-title":"Advanced glycation end products: new clinical and molecular perspectives","volume":"18","author":"Salazar","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2025020513212235900_bib38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/732450","article-title":"Advanced Glycation end products enhance macrophages polarization into M1 phenotype through activating RAGE\/NF-\u03baB pathway","volume":"2015","author":"Jin","year":"2015","journal-title":"Biomed Res Int"},{"key":"2025020513212235900_bib39","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/sj.ki.5002456","article-title":"Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor","volume":"72","author":"Chuang","year":"2007","journal-title":"Kidney Int"},{"key":"2025020513212235900_bib40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.krcp.2015.05.002","article-title":"Transforming growth factor-\u03b2 receptor 2 gene polymorphisms are associated with end-stage renal disease","volume":"34","author":"Ki","year":"2015","journal-title":"Kidney Res Clin Pract"},{"key":"2025020513212235900_bib41","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int"},{"key":"2025020513212235900_bib42","doi-asserted-by":"publisher","first-page":"F716","DOI":"10.1152\/ajprenal.00314.2016","article-title":"Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets","volume":"312","author":"Pichler","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025020513212235900_bib43","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.semnephrol.2007.02.001","article-title":"Inflammatory cells in renal injury and repair","volume":"27","author":"Ferenbach","year":"2007","journal-title":"Semin Nephrol"},{"key":"2025020513212235900_bib44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1053\/j.ackd.2017.12.002","article-title":"Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease","volume":"25","author":"Alicic","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"2025020513212235900_bib45","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-physiol-022516-034227","article-title":"Mechanisms of renal fibrosis","volume":"80","author":"Humphreys","year":"2018","journal-title":"Annu Rev Physiol"},{"key":"2025020513212235900_bib46","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2025020513212235900_bib47","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2025020513212235900_bib48","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2025020513212235900_bib49","doi-asserted-by":"publisher","first-page":"111254","DOI":"10.1016\/j.mce.2021.111254","article-title":"Renin-angiotensin system and inflammation update","volume":"529","author":"Cantero-Navarro","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"2025020513212235900_bib50","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2025020513212235900_bib51","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2025020513212235900_bib52","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2025020513212235900_bib53","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2025020513212235900_bib54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","author":"EMPA-KIDNEY Collaborative Group","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025020513212235900_bib55","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet North Am Ed"},{"key":"2025020513212235900_bib56","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology Consensus Statement: comprehensive type 2 diabetes management algorithm\u20132023 update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"key":"2025020513212235900_bib57","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.2337\/dc24-SINT","article-title":"Standards of care in diabetes\u20132024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"2025020513212235900_bib58","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/ckj\/sfad045","article-title":"Searching in the maze: sodium-glucose cotransporter-2 inhibitors in kidney transplant recipients to improve survival","volume":"16","author":"Oliveras","year":"2023","journal-title":"Clin Kidney J"},{"key":"2025020513212235900_bib59","volume-title":"meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis (CANARY)","author":"Medicine NLo"},{"key":"2025020513212235900_bib60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"2025020513212235900_bib61","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.ajkd.2020.08.003","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation","volume":"77","author":"Tuttle","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2025020513212235900_bib62","doi-asserted-by":"publisher","first-page":"e167700","DOI":"10.1172\/JCI167700","article-title":"Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors","volume":"133","author":"Tuttle","year":"2023","journal-title":"J Clin Invest"},{"key":"2025020513212235900_bib63","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.3390\/cells12151975","article-title":"Slowing the progression of diabetic kidney disease","volume":"12","author":"Blazek","year":"2023","journal-title":"Cells"},{"key":"2025020513212235900_bib64","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.kint.2018.04.025","article-title":"Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice","volume":"94","author":"Tanaka","year":"2018","journal-title":"Kidney Int"},{"key":"2025020513212235900_bib65","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","article-title":"Regulation and metabolic functions of mTORC1 and mTORC2","volume":"101","author":"Szwed","year":"2021","journal-title":"Physiol Rev"},{"key":"2025020513212235900_bib66","doi-asserted-by":"publisher","first-page":"107954","DOI":"10.1016\/j.celrep.2020.107954","article-title":"Proximal tubule mTORC1 is a central player in the pathophysiology of diabetic nephropathy and its correction by SGLT2 inhibitors","volume":"32","author":"Kogot-Levin","year":"2020","journal-title":"Cell Rep"},{"key":"2025020513212235900_bib67","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/ijms19030818","article-title":"mTORC1 and nutrient homeostasis: the central role of the lysosome","volume":"19","author":"Rabanal-Ruiz","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025020513212235900_bib68","doi-asserted-by":"publisher","first-page":"F1217","DOI":"10.1152\/ajprenal.00294.2016","article-title":"Solute transport and oxygen consumption along the nephrons: effects of Na+ transport inhibitors","volume":"311","author":"Layton","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025020513212235900_bib69","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1172\/JCI120849","article-title":"Mitochondrial dysfunction in pathophysiology of heart failure","volume":"128","author":"Zhou","year":"2018","journal-title":"J Clin Invest"},{"key":"2025020513212235900_bib70","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"2025020513212235900_bib71","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1111\/dom.15191","article-title":"Mediators between canagliflozin and renoprotection vary depending on patient characteristics: insights from the CREDENCE trial","volume":"25","author":"Doi","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025020513212235900_bib72","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"2025020513212235900_bib73","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"2025020513212235900_bib74","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2025020513212235900_bib75","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamacardio.2023.1505","article-title":"Modifiability of composite cardiovascular risk associated with chronic kidney disease in type 2 diabetes with finerenone","volume":"8","author":"Agarwal","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2025020513212235900_bib76","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1124\/dmd.118.083337","article-title":"Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro","volume":"46","author":"Gerisch","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"2025020513212235900_bib77","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2025020513212235900_bib78","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025020513212235900_bib79","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2025020513212235900_bib80","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ehjcvp\/pvac054","article-title":"Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease","volume":"9","author":"Filippatos","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025020513212235900_bib81","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1210\/clinem\/dgad144","article-title":"Efficacy and safety of low-dose spironolactone for chronic kidney disease in type 2 diabetes","volume":"108","author":"Oiwa","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2025020513212235900_bib82","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"2025020513212235900_bib83","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2025020513212235900_bib84","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2025020513212235900_bib85","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet North Am Ed"},{"key":"2025020513212235900_bib86","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025020513212235900_bib87","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int"},{"key":"2025020513212235900_bib88","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"2025020513212235900_bib89","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2025020513212235900_bib90","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1139\/bcb-2021-0365","article-title":"Cardiovascular protective effects of GLP-1: a focus on the MAPK signaling pathway","volume":"100","author":"Zhao","year":"2022","journal-title":"Biochem Cell Biol"},{"key":"2025020513212235900_bib91","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"key":"2025020513212235900_bib92","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.metabol.2012.03.002","article-title":"GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases","volume":"61","author":"Hendarto","year":"2012","journal-title":"Metabolism"},{"key":"2025020513212235900_bib93","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3109\/08977194.2015.1125349","article-title":"Exendin-4 attenuates renal tubular injury by decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice","volume":"33","author":"Sancar-Bas","year":"2015","journal-title":"Growth Factors"},{"key":"2025020513212235900_bib94","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"key":"2025020513212235900_bib95","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1681\/ASN.2006070778","article-title":"Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db\/db mice","volume":"18","author":"Park","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2025020513212235900_bib96","doi-asserted-by":"publisher","first-page":"151427","DOI":"10.1016\/j.semnephrol.2023.151427","article-title":"Incorporating evidence and guidelines for personalized care of diabetes and chronic kidney disease","volume":"43","author":"Neumiller","year":"2023","journal-title":"Semin Nephrol"},{"key":"2025020513212235900_bib97","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025020513212235900_bib98","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41581-024-00827-z","article-title":"Combination therapy for kidney disease in people with diabetes mellitus","volume":"20","author":"van Raalte","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2025020513212235900_bib99","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1124\/jpet.113.203869","article-title":"Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats","volume":"345","author":"Kojima","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"2025020513212235900_bib100","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025020513212235900_bib101","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"2025020513212235900_bib102","doi-asserted-by":"publisher","first-page":"F1295","DOI":"10.1152\/ajprenal.00498.2019","article-title":"Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy","volume":"318","author":"Hudkins","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025020513212235900_bib103","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.lfs.2013.12.018","article-title":"Addition of ET(A) receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5\/6 nephrectomized Ren-2 transgenic rats","volume":"118","author":"Certikova Chabova","year":"2014","journal-title":"Life Sci"},{"key":"2025020513212235900_bib104","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.122.059150","article-title":"Renal and vascular effects of combined SGLT2 and angiotensin-converting enzyme inhibition","volume":"146","author":"Lytvyn","year":"2022","journal-title":"Circulation"},{"key":"2025020513212235900_bib105","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1161\/CIRCULATIONAHA.122.061033","article-title":"Kidney hemodynamic effects of angiotensin receptor blockade, sodium-glucose cotransporter-2 inhibition alone, and their combination: a crossover randomized trial in people with type 2 diabetes","volume":"146","author":"Scholtes","year":"2022","journal-title":"Circulation"},{"key":"2025020513212235900_bib106","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1161\/CIRCULATIONAHA.121.057934","article-title":"Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial","volume":"145","author":"Lam","year":"2022","journal-title":"Circulation"},{"key":"2025020513212235900_bib107","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/dom.14883","article-title":"Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use","volume":"25","author":"Rossing","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025020513212235900_bib108","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ekir.2021.12.013","article-title":"The kidney protective effects of the sodium-glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists","volume":"7","author":"Provenzano","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025020513212235900_bib109","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025020513212235900_bib110","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"2025020513212235900_bib111","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025020513212235900_bib112","doi-asserted-by":"publisher","first-page":"sfad249","DOI":"10.1093\/ckj\/sfad249","article-title":"Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial","volume":"17","author":"Marup","year":"2023","journal-title":"Clin Kidney J"},{"key":"2025020513212235900_bib113","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/dom.15033","article-title":"Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: a randomized cross-over clinical study","volume":"25","author":"van der Aart-van der Beek","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025020513212235900_bib114","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1111\/dom.14410","article-title":"Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial","volume":"23","author":"van Ruiten","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2025020513212235900_bib115","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet North Am Ed"},{"key":"2025020513212235900_bib116","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet North Am Ed"},{"key":"2025020513212235900_bib117","article-title":"A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE)"},{"key":"2025020513212235900_bib118","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025020513212235900_bib119","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1053\/j.ajkd.2020.01.015","article-title":"Osmotic nephrosis and acute kidney injury associated with SGLT2 inhibitor use: a case report","volume":"76","author":"Phadke","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2025020513212235900_bib120","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":". Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet North Am Ed"},{"key":"2025020513212235900_bib121","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"2025020513212235900_bib122","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1161\/CIRCULATIONAHA.123.068524","article-title":"Accelerated risk-based implementation of guideline-directed medical therapy for type 2 diabetes and chronic kidney disease","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/Supplement_1\/i3\/61766429\/gfae212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/Supplement_1\/i3\/61766429\/gfae212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T08:25:00Z","timestamp":1738743900000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/Supplement_1\/i3\/8002193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":122,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,2,5]]},"published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae212","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]}}}